Leukocyte reduced: Prevents sensitization in patients who may require bone marrow transplant
Irradiated: Eliminates capacity of T-cells to proliferate (prevents Transfusion-associated graft-versus-host disease)
If tranfusion required for crashing patient, do not delay tranfusion of uncrossed blood to irradiate<unk>  beforehand
Requires minimum 25 Gy irradiation, not to exceed 50 Gy for all:
Packed red cells
Platelets
Granulocyte components, regardless of immunocompetency
First or second degree relatives, regardless of immunocompetency
HLA-selected components, regardless of immunocompetency
Irradiated<unk>  should be administered shortly after irradiation
Those<unk>  not used for intended recipient may be returned safely to stock for others not requiring irradiated components, though with reduced shelf life
Not necessary to irradiate FFP, cryoprecipitate, fractioned plasma<unk> 
Packed red cells
Platelets
Granulocyte components, regardless of immunocompetency
First or second degree relatives, regardless of immunocompetency
HLA-selected components, regardless of immunocompetency
Immunocompromised stem cell recipients
Organ transplant recipients
Patients undergoing marrow transplantation
Intrauterine transfusion
Neonatal exchange transfusions
Premature and low birthweight neonates
Hodgkin lymphoma
Congenital cell-mediated immunodeficiencies (DiGeorge, Wiskott-Aldrich, Leiner's, 5'-nucelotidase deficiency)
Acquired immunodeficiencies to include:
Leukemia, CLL
Aplastic anemia
Neutropenia
Patients receiving:
Purine analogue chemotherapies (fludarabine, cladribine, deoxycoformicin, bendamustine, clofarabine, etc.)
Certain biologic immunosuppresants (alemtuzumab)
Donations from biologic relatives
Donations from HLA-matched donors
Genetically homogenous populations
Probably indicated int:
Hematologic malignancies other than Hodgkin lymphoma
Solid tumors treated with cytotoxic agents
Leukemia, CLL
Aplastic anemia
Neutropenia
Purine analogue chemotherapies (fludarabine, cladribine, deoxycoformicin, bendamustine, clofarabine, etc.)
Certain biologic immunosuppresants (alemtuzumab)
Hematologic malignancies other than Hodgkin lymphoma
Solid tumors treated with cytotoxic agents
Chronically transfused
Cardiac surgery
Solid organ or stem cell transplant recipients, before and after
Previous febrile nonhemolytic transfusion reactions
CMV seronegative patients at risk
HIV, AIDS
Concurrent, non-severe common viral infection
Rituximab treatment
Routine solid organ transplant
Routine infant cardiac surgery
Blood products
Whole blood
Hemostatic agents
Massive transfusion
Massive transfusion 
Fresh frozen plasma
Platelet transfusion
Packed red blood cells